semaglutide effect on liver might be a key for breaking the vicious cycle of metabolically associated fatty disease spectrum? Semaglutide effectively treats liver disease

Cardiovascular outcome trials (CVOTs) with GLP-1RAs evaluated seven agents, with liraglutide, semaglutide, and dulaglutide showing significant CV and renal benefits

doi:10.1093/asj/sjac179

High-yield reporting fields for suspected semaglutide-related vaginal symptoms include: dose and escalation dates, concomitant SGLT2 inhibitor use, antibiotic/antifungal use, menopausal status/HRT, diabetes control markers, symptom description with onset/offset, objective test results (pH, microscopy/NAAT), and dechallenge/rechallenge outcomes if they occur

We observed that brief pretreatment with GLP-1(2836) versus the scrambled control increased glycolysis by 36% (extracellular acidification rate [ECAR]: 14.5 1.6 vs

Instead of clearing abnormal tissue, they may help create conditions that allow lesions to survive